The three doses of the COVID-19 vaccine also work against OMICRON, said PFIZER and BioNTech.
Preliminary tests by PFIZER and BioNTech show that three doses of COVID-19 vaccine also work against OMICRON. The first two doses of the COVID-19 vaccine work significantly against OMICRON, but the third dose of the COVID-19 vaccine, in particular, works much better against OMICRON, about 25 times more than the two doses.
Since two doses are not sufficient for OMICRON variant. That’s why work is underway to observe two doses comparable to titers that can be combined with a higher level of protection.
Since 80% of the spike proteins recognized by CD8 + T cells cannot be affected by mutations in the ectopic Omicron variant. That’s why the two doses are still not able to provide serious protection against OMICRON.
That’s why companies are working to develop an alternative-specific vaccine that can provide serious protection against OMICRON. It is expected to be available by March 2022.
“Our preliminary, first dataset indicate that a third dose could still offer a sufficient level of protection from disease of any severity caused by the Omicron variant,” Sahin said in a joint statement.
However, Pfizer and BioNTech said in their study that those who took the first two doses of the COVID-19 vaccine were less likely to fight omikron infection. However, many experts believe that the COVID-19 vaccine will provide protection against serious diseases for those who have taken the first two doses. Although neutralization studies do not shed much light on that aspect.Although neutralization studies do not shed much light on that aspect.
At the same time, the data suggest that a person has previously recovered from a corona infection or has been vaccinated against Covid-19. They will mount a response that restores overall protection against Omicron.
Vaccines for the current Covid-19. Yet Pfizer and other vaccine makers are not sitting still. They have started making vaccines specifically for Omicron. If a specific vaccine is needed for Omicron. Or if Omicron takes on a new form that did not work on the previous Covid-19 vaccine.
Then the manufacturers will advise people to adopt the specific vaccine that they have started to make for Omicron. If the specific vaccine for Omicron is a complete success, Pfizer and other vaccine manufacturers will be able to market it extensively.
Pfizer-BioNTech COVID-19 vaccine, based on BioNTech-owned mRNA technology, has been developed by both BioNTech and Pfizer.
And BioNTech is the holder of marketing approvals in the United States, the European Union, the United Kingdom, Canada, and other countries.
That’s why the United States, in a joint venture with Pfizer, has approved emergency use in other countries.
Countries that were initially granted approval for emergency use. Plans are underway to submit approvals to all those countries.
U.S. Indication approves how the vaccine will be given.
Rules for vaccinating people five years of age or older
Those 5 years of age or older are allowed to take 2-doses at 3-week intervals. And individuals 12 years of age or older who have been given a second dose of immunocompromised for at least 4 weeks have been advised to give them a third primary series dose. Indication.
Booster doses are recommended for people 18 years of age or older
People 18 years of age or older who have been given the initial series dose. They can be given a booster dose after at least six months.
And this booster dose should be given to people 18 years of age or older and those who have completed the initial vaccination with a different approved COVID-19 vaccine should be given a booster dose.
Also, people who are given booster doses should check with their healthcare provider.
Rich nations are starting to stockpile vaccines again to deal with the new coronary omicron variant. Last Thursday, the World Health Organization issued a warning.
The World Health Organization (WHO) also says that minimal countries are at risk a year after the vaccine was introduced in the fight against corona. Adequate amounts of vaccines are not reaching the poorest and least developed countries in the world to deal with the new virus.
Countries have been able to ensure that only 13 percent of people have been vaccinated. On the other hand, rich and developed countries are working to develop more high-quality vaccines to deal with the omicron variant.
[su_youtube url=”https://youtu.be/z-Z8tkxQyNg” width=”200″ height=”200″]